Nektar Therapeutics

At #EADV2024, Nektar is presenting three posters, including one poster featuring new biomarker analysis data of REZPEG, our novel first-in-class Treg cell stimulator, currently being evaluated in two Phase 2b studies in #atopicdermatitis and #alopeciaareata. Learn more: https://bit.ly/3MZOnaj   

Nearly 2% of people across the world will experience #alopeciaareata at some point in their lifetime. We’re proud to be evaluating our lead program, REZPEG, in a Phase 2b study for the treatment of alopecia areata and other #autoimmunedisorders. Learn more: https://bit.ly/48e4NF2 #AlopeciaAreataAwarenessMonth

It’s #AtopicEczemaDay. Dedicated to developing novel therapies for patients affected by #autoimmunedisorders, Nektar is evaluating our novel regulatory T-cell selective IL-2 conjugate, REZPEG, for potential treatment of inflammatory skin diseases, including #atopicdermatitis. Learn more: https://bit.ly/48e4NF2

This month, Nektar is presenting at two investor conferences to discuss the potential of our #immunology pipeline focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory disease. More details: https://bit.ly/4gcfRac 

We had a great time last weekend at #EczemaExpo2024, where Nektar proudly was a sponsor. We connected with the #eczema communities to discuss research and advancements in treatments. Learn about our promising #immunology and #inflammation pipeline of treatments that address underlying immunological dysfunctions: https://bit.ly/48e4NF2

At #EULAR2024, Nektar highlighted preclinical data from NKTR-0165, our TNFR2 agonist for the potential treatment of #autoimmune disorders. More details from the presentation here: https://bit.ly/4b9NUMa

We’re looking forward to presenting at two upcoming investor conferences in June. Join to hear about the therapies Nektar is developing across our #immunology and #inflammation pipeline and anticipated milestones ahead: https://bit.ly/4aGlRnt  

We’re excited that our Chief Research and Development Officer, Jonathan Zalevsky, will be presenting at the Annual Treg-Directed Therapies Summit this week. Learn more about his thoughts on the field of Treg therapies: https://bit.ly/3UvohPJ

Today, we announced first quarter 2024 financial results. Join us on our conference call at 5:00 p.m. ET/2:00 p.m. PT. Press release and information here: https://bit.ly/3yg5vV9

We look forward to the #Dermatology Drug Development Summit this week! Nektar’s Chief Research and Development Officer, Jonathan Zalevsky, will present on REZPEG, our lead pipeline candidate being evaluated in #inflammatory #skindiseases and will participate in a panel. For more information please visit here: https://lnkd.in/d-d2PYU